Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price ...

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

BOSTON, October 25, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous ...

Making a noteworthy insider sell on October 9, ITEM SECOND IRR TRUST FBO JACOB J WESTPHAL ua of JEFFREY R WESTPHAL dated October , 10% Owner at Vertex VERX, is reported in the latest SEC filing.

Vertex (VERX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

More than three-quarters (77%) of health care providers surveyed stated that treating moderate-to-severe acute pain with ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

With an FDA decision looming over its first foray into the acute pain space, Vertex Pharmaceuticals has commissioned a pair of surveys to take stock of that space. The resulting report ...